Capricor Sues Nippon Shinyaku Over Distribution Agreement
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2 days ago
0mins
Should l Buy CAPR?
Capricor Therapeutics (CAPR) announced that it has filed a lawsuit against Nippon Shinyaku (NPNKF) and its U.S. subsidiary, NS Pharma, over the parties' U.S. distribution agreement for Deramiocel, Capricor's investigational cell therapy for the treatment of Duchenne muscular dystrophy. "Deramiocel represents one of the most significant therapeutic advances for DMD, addressing both its skeletal and cardiac manifestations. NS Pharma's inaction may now jeopardize patients' access to this life-changing treatment," the company said. Capricor's complaint details how "a fundamental pricing flaw in the Commercialization and Distribution Agreement with NS Pharma will prevent patients covered by Medicare, Medicaid, or private insurance from accessing the therapy. Capricor has sought to work in good faith to fix this pricing mechanism with NS Pharma, but NS Pharma has refused to compromise. NS Pharma also has failed to adequately prepare for commercial launch of Deramiocel, and Capricor is now taking legal action to ensure there is a path for Deramiocel to reach the patients who urgently need it." The U.S. Food and Drug Administration has granted Deramiocel Priority Review, with a target PDUFA action date of August 22, 2026. The FDA review process and expected timing remain unchanged.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CAPR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CAPR
Wall Street analysts forecast CAPR stock price to rise
7 Analyst Rating
7 Buy
0 Hold
0 Sell
Strong Buy
Current: 33.940
Low
45.00
Averages
51.57
High
60.00
Current: 33.940
Low
45.00
Averages
51.57
High
60.00
About CAPR
Capricor Therapeutics, Inc. is a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment and prevention of rare diseases. The Company's program is focused on the development and commercialization of a cell therapy technology comprised of cardiosphere-derived cells (CDCs) for the treatment of Duchenne muscular dystrophy (DMD). Its lead product candidate deramiocel (also referred to as CAP-1002), is an allogeneic cardiac-derived cell therapy. CAP-1002 is advancing through Phase III clinical development for the treatment of Duchenne muscular dystrophy (DMD). CAP-1002 demonstrates immunomodulatory, antifibrotic, and regenerative actions specifically tailored for dystrophinopathies and heart disease. It leverages its exosome technology, using its StealthX platform in preclinical development focused on the areas of vaccinology, targeted delivery of oligonucleotides, proteins, and small molecule therapeutics.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Capricor Executive Exercises Stock Options in $793K Transaction
- Executive Stock Transaction: Karen Krasney, EVP of Capricor Therapeutics, exercised 25,000 stock options and immediately sold them for approximately $793,000, indicating executive confidence in the company's future prospects.
- Shareholding Changes: Following the transaction, Krasney's direct equity position was reduced by 45.01%, yet she retains 30,547 common shares and 56,261 unexercised options, highlighting her continued material exposure to the company.
- Market Performance: Capricor boasts a market capitalization of $1.75 billion, with a remarkable 335% increase in stock price over the past year, rebounding from a 52-week low of $4.30 to a high of $40.37, reflecting strong market interest in its clinical pipeline.
- Transaction Plan Context: This sale was executed under a 10b5-1 trading plan established by Krasney in December 2025, indicating that her decision to sell was pre-scheduled, which reflects confidence in the company's fundamentals rather than a reaction to current events.
See More
Krasney Sells Shares for Diversification Under 10b5-1 Plan
- Share Sale Overview: On May 1, 2026, Krasney sold 25,000 common shares at a weighted average price of $31.70, totaling approximately $793,000, which reduced her direct holdings to 30,547 shares, indicating a strategic adjustment in her equity position.
- Options Exercise and Sale: This transaction stemmed from a 10b5-1 trading plan established in December 2025, indicating that the timing and size were predetermined, and all shares were directly held, with no indirect entities involved, thus minimizing market reaction concerns.
- Holding and Options Status: Krasney retains 56,261 unexercised options with a strike price of $3.18, while the current stock price is $30.38, providing approximately $27 of intrinsic value per option, which signifies her continued material exposure to Capricor Therapeutics' equity.
- Market Performance and Investor Focus: Capricor Therapeutics' stock has surged from a 52-week low of $4.30 to a high of $40.37, though it has recently pulled back, prompting investors to evaluate whether the clinical pipeline justifies the current valuation, reflecting a cautious market sentiment regarding future growth potential.
See More
Capricor Sues Nippon Shinyaku Over Pricing Flaw
- Lawsuit Reason: Capricor Therapeutics is suing Nippon Shinyaku due to a 'fundamental pricing flaw' in their 2022 agreement, resulting in an approximately 11% drop in stock price during Friday trading.
- Agreement Details: The agreement granted Nippon Shinyaku exclusive rights to commercialize and distribute Deramiocel (CAP-1002), a treatment for Duchenne muscular dystrophy in the U.S., with Capricor alleging inadequate preparation for the product's commercial launch.
- Legal Demands: Capricor seeks rescission of the U.S. Distribution Agreement and a declaratory judgment affirming its right to distribute Deramiocel directly or through other distributors, along with preliminary injunctive relief and other equitable remedies.
- FDA Progress: Capricor received a Complete Response Letter from the FDA in July 2025 addressing concerns regarding Deramiocel, with a new action date set for August 22, 2026, and if approved, the drug could become the first therapy targeting both skeletal and cardiac manifestations of Duchenne muscular dystrophy.
See More
Middle East Tensions Ease as Investors Await Jobs Data
- Middle East Stability: President Trump confirmed that the ceasefire with Iran remains intact despite naval tensions in the Strait of Hormuz, which has boosted market sentiment as investors remain optimistic about upcoming economic data.
- Nasdaq Futures Rise: As of 4:00 a.m. ET Friday, Nasdaq futures gained 0.6% and S&P 500 futures rose 0.3%, indicating investor optimism ahead of the highly anticipated jobs data, which could further propel the stock market.
- Nvidia and Iren Partnership: Iren's stock surged 9% after securing a massive $3.4 billion AI cloud contract with Nvidia, overshadowing a revenue miss in Q3, demonstrating the ongoing enthusiasm for investments in the AI sector.
- Cloudflare Layoffs Impact: Cloudflare announced a 20% workforce reduction and lowered its Q2 guidance, leading to a 17% drop in its stock during premarket trading, reflecting market concerns about its future growth prospects.
See More
Capricor Sues NS Pharma Over Deramiocel Launch Issues
- Legal Action Impact: Capricor has filed a lawsuit against NS Pharma, alleging failure to prepare for the commercial rollout of its DMD therapy Deramiocel, resulting in a 13% drop in after-hours trading, reflecting investor concerns about the company's future.
- Pricing Structure Issues: Capricor claims that the current pricing structure could render Deramiocel commercially unviable under Medicare reimbursement rules, potentially limiting patient access as hospitals and treatment centers may incur losses administering the therapy.
- Launch Preparation Delays: The lawsuit alleges that NS Pharma slowed down launch preparations after the FDA issued a Complete Response Letter, disrupting market access and pricing strategies, which could adversely affect the drug's approval and commercialization.
- Investor Focus on FDA: As the FDA continues its review of Deramiocel, Capricor's shareholders are closely monitoring leadership changes within the agency, with market sentiment becoming extremely bullish amid high message volume, despite the ongoing legal challenges.
See More
FDA Leadership Contender Sparks Market Interest
- FDA Leadership Consideration: Hemmati is reportedly being considered for a leadership role at the FDA's Center for Biologics Evaluation and Research, which could influence the agency's approval strategies for gene and cell therapies, particularly regarding rare disease treatments.
- Drug Approval Perspective: Hemmati stated on social media that FDA approval is merely a safety check, emphasizing patient and physician choice, which may impact investor confidence in Capricor, leading to an 8% decline in its stock on Friday.
- DMD Therapy Decision: Capricor awaits an FDA decision on its DMD therapy, Deramiocel, expected by August 22, with prior clinical trials showing a 54% slowing in upper-limb function decline, potentially affecting the company's future market performance.
- Market Sentiment Analysis: Despite regulatory pressures, retail sentiment for CAPR remains 'bullish', reflecting market expectations for potential rewards tied to clinical trial success, with the stock surging 143% over the past year.
See More
Capricor Executive Exercises Stock Options in $793K Transaction
- Executive Stock Transaction: Karen Krasney, EVP of Capricor Therapeutics, exercised 25,000 stock options and immediately sold them for approximately $793,000, indicating executive confidence in the company's future prospects.
- Shareholding Changes: Following the transaction, Krasney's direct equity position was reduced by 45.01%, yet she retains 30,547 common shares and 56,261 unexercised options, highlighting her continued material exposure to the company.
- Market Performance: Capricor boasts a market capitalization of $1.75 billion, with a remarkable 335% increase in stock price over the past year, rebounding from a 52-week low of $4.30 to a high of $40.37, reflecting strong market interest in its clinical pipeline.
- Transaction Plan Context: This sale was executed under a 10b5-1 trading plan established by Krasney in December 2025, indicating that her decision to sell was pre-scheduled, which reflects confidence in the company's fundamentals rather than a reaction to current events.
See More
Krasney Sells Shares for Diversification Under 10b5-1 Plan
- Share Sale Overview: On May 1, 2026, Krasney sold 25,000 common shares at a weighted average price of $31.70, totaling approximately $793,000, which reduced her direct holdings to 30,547 shares, indicating a strategic adjustment in her equity position.
- Options Exercise and Sale: This transaction stemmed from a 10b5-1 trading plan established in December 2025, indicating that the timing and size were predetermined, and all shares were directly held, with no indirect entities involved, thus minimizing market reaction concerns.
- Holding and Options Status: Krasney retains 56,261 unexercised options with a strike price of $3.18, while the current stock price is $30.38, providing approximately $27 of intrinsic value per option, which signifies her continued material exposure to Capricor Therapeutics' equity.
- Market Performance and Investor Focus: Capricor Therapeutics' stock has surged from a 52-week low of $4.30 to a high of $40.37, though it has recently pulled back, prompting investors to evaluate whether the clinical pipeline justifies the current valuation, reflecting a cautious market sentiment regarding future growth potential.
See More
Capricor Sues Nippon Shinyaku Over Pricing Flaw
- Lawsuit Reason: Capricor Therapeutics is suing Nippon Shinyaku due to a 'fundamental pricing flaw' in their 2022 agreement, resulting in an approximately 11% drop in stock price during Friday trading.
- Agreement Details: The agreement granted Nippon Shinyaku exclusive rights to commercialize and distribute Deramiocel (CAP-1002), a treatment for Duchenne muscular dystrophy in the U.S., with Capricor alleging inadequate preparation for the product's commercial launch.
- Legal Demands: Capricor seeks rescission of the U.S. Distribution Agreement and a declaratory judgment affirming its right to distribute Deramiocel directly or through other distributors, along with preliminary injunctive relief and other equitable remedies.
- FDA Progress: Capricor received a Complete Response Letter from the FDA in July 2025 addressing concerns regarding Deramiocel, with a new action date set for August 22, 2026, and if approved, the drug could become the first therapy targeting both skeletal and cardiac manifestations of Duchenne muscular dystrophy.
See More
Middle East Tensions Ease as Investors Await Jobs Data
- Middle East Stability: President Trump confirmed that the ceasefire with Iran remains intact despite naval tensions in the Strait of Hormuz, which has boosted market sentiment as investors remain optimistic about upcoming economic data.
- Nasdaq Futures Rise: As of 4:00 a.m. ET Friday, Nasdaq futures gained 0.6% and S&P 500 futures rose 0.3%, indicating investor optimism ahead of the highly anticipated jobs data, which could further propel the stock market.
- Nvidia and Iren Partnership: Iren's stock surged 9% after securing a massive $3.4 billion AI cloud contract with Nvidia, overshadowing a revenue miss in Q3, demonstrating the ongoing enthusiasm for investments in the AI sector.
- Cloudflare Layoffs Impact: Cloudflare announced a 20% workforce reduction and lowered its Q2 guidance, leading to a 17% drop in its stock during premarket trading, reflecting market concerns about its future growth prospects.
See More
Capricor Sues NS Pharma Over Deramiocel Launch Issues
- Legal Action Impact: Capricor has filed a lawsuit against NS Pharma, alleging failure to prepare for the commercial rollout of its DMD therapy Deramiocel, resulting in a 13% drop in after-hours trading, reflecting investor concerns about the company's future.
- Pricing Structure Issues: Capricor claims that the current pricing structure could render Deramiocel commercially unviable under Medicare reimbursement rules, potentially limiting patient access as hospitals and treatment centers may incur losses administering the therapy.
- Launch Preparation Delays: The lawsuit alleges that NS Pharma slowed down launch preparations after the FDA issued a Complete Response Letter, disrupting market access and pricing strategies, which could adversely affect the drug's approval and commercialization.
- Investor Focus on FDA: As the FDA continues its review of Deramiocel, Capricor's shareholders are closely monitoring leadership changes within the agency, with market sentiment becoming extremely bullish amid high message volume, despite the ongoing legal challenges.
See More
FDA Leadership Contender Sparks Market Interest
- FDA Leadership Consideration: Hemmati is reportedly being considered for a leadership role at the FDA's Center for Biologics Evaluation and Research, which could influence the agency's approval strategies for gene and cell therapies, particularly regarding rare disease treatments.
- Drug Approval Perspective: Hemmati stated on social media that FDA approval is merely a safety check, emphasizing patient and physician choice, which may impact investor confidence in Capricor, leading to an 8% decline in its stock on Friday.
- DMD Therapy Decision: Capricor awaits an FDA decision on its DMD therapy, Deramiocel, expected by August 22, with prior clinical trials showing a 54% slowing in upper-limb function decline, potentially affecting the company's future market performance.
- Market Sentiment Analysis: Despite regulatory pressures, retail sentiment for CAPR remains 'bullish', reflecting market expectations for potential rewards tied to clinical trial success, with the stock surging 143% over the past year.
See More
